TREATMENT OF A PATIENT WITH SEVERE MENSTRUAL MIGRAINE USING THE DEPOT LHRH ANALOG ZOLADEX

被引：20

作者：

HOLDAWAY, IM

PARR, CE

FRANCE, J

机构：

[1] Department of Medicine, Auckland Hospital, Auckland

[2] Department of Obstetrics and Gynaecology, Middlemore Hospital, Auckland

[3] Post Graduate School of Obstetrics and Gynaecology, National Women's Hospital, Auckland

来源：

AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY | 1991年 / 31卷 / 02期

关键词：

D O I：

10.1111/j.1479-828X.1991.tb01808.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Migraine occurring at menstruation is frequently difficult to treat. A 38-year-old woman with exceptionally severe menstrual migraine was treated by temporary ovarian suppression using Zoladex, a long acting luteinizing hormone-releasing hormone agonist. There was prompt relief of headache, and after several months of treatment the patient elected to undergo surgical oophorectomy with subsequent resolution of her migraine. A trial of reversible hypogonadism using an LHRH agonist may thus be helpful in predicting the result of surgical castration in this situation.

引用

页码：164 / 165

页数：2

共 11 条

[1]

Stein MT, Hockaday JM, Hockaday TD, Migraine and reproductive hormones throughout the menstrual cycle, Lancet, 1, pp. 543-545, (1978)

[2]

Somerville BW, Estrogen‐withdrawal migraine: 1‐ Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration, Neurology, 25, pp. 239-244, (1975)

[3]

Somerville BW, Estrogen‐withdrawal migraine: 2‐ Attempted prophylaxis by continuous estradiol administration, Neurology, 25, pp. 245-250, (1975)

[4]

Dennerstein L., Laby B., Burrows GD, Hyman GJ, Headache and sex hormone therapy, Headache, 18, pp. 146-153, (1978)

[5]

Bousser MG, de Lignieres B., Vincens M., Mas JL, Mauvais-Jarvis P., Prevention of menstrual migraine by percutaneous oestradiol treatment, Advances in Headache Research, pp. 135-138, (1987)

[6]

Magos A., Zilkha K., Studd J., Treatment of menstrual migraine by oestradiol implants, J Neurol Neurosurg Psychiat, 46, pp. 1044-1046, (1983)

[7]

Ad Hoc Committee on classification of headache, JAMA, 179, pp. 717-718, (1962)

[8]

Dahl KD, Pavlou SN, Kovacs WJ, Hsueh AJ, The changing ratio of serum bioactive to immunoreactive follicle‐stimulating hormone in normal men following treatment with a potent gonadotropin releasing hormone agonist, J Clin Endocrinol Metab, 63, pp. 792-794, (1986)

[9]

Walker KJ, Nicholson RI, Turkes AO, Turkes A., Griffiths K., Robinson M., Crispin Z., Dris S., Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma, Lancet, 3, pp. 413-415, (1983)

[10]

Williams MR, Walker KJ, Turkes A., Blarney RW, Nicholson RI, The use of an LH‐RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer, Br J Cancer, 53, pp. 629-636, (1986)

← 1 2 →